Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma

Haematologica

Volumn 100, Issue 7, 2015, Pages e289-e291

  Ocio, Enrique M ^a   Dávila, Julio ^a   Caballero, Juan Carlos ^a   Alonso, Sara ^a   De La Calle, Verónica González ^a   García Sanz, Ramón ^a   Gazi, Lucien ^c   Opio, Socrates ^c   Jiménez, Mónica ^c   San Miguel, Jesús F ^b   Mateos, María Victoria ^a  

^a Centro de Investigacion del Cancer   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Maintenance; Panobinostat; Progression free survival; Relapsed multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; M PROTEIN; MELPHALAN; PANOBINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ADULT; ANEMIA; ANOREXIA; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEMALE; HUMAN; IMMUNOPHENOTYPING; LETTER; LONG TERM CARE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMACYTOMA; PROGRESSION FREE SURVIVAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; PATHOLOGY; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS; BORTEZOMIB; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE;

EID: 84933563017     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124164     Document Type: Letter

References (12)

1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520.
3. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group Study. Leukemia. 2012;26(1):149-157.
4. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-542.
5. Ocio EM, San Miguel JF. The DAC system and associations with multiple myeloma. Invest New Drugs. 2010;28 (Suppl 1):S28-35.
6. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66(11):5781-5789.
7. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108(10):3441-3449.
8. Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95(5):794-803.
9. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.
10. San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31(29):3696-3703.
11. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331-2337
12. Wolf JL, Siegel D, Goldschmidt H, et al. Phase II trial of the pandeacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012; 53(9):1820-1823.